Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt ...
Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...
We came across a bullish thesis on BioMarin Pharmaceutical Inc. on Value investing subreddit by BearWithMeGM. In this article ...
Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease December 1, 2025 8:00 ...
Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...
GlobalData on MSN
Belite eyes tinlarebant approval after late-stage Stargardt success
While GlobalData analyst Sara Reci touted the DRAGON results as a “breakthrough” in STGD1, she noted that barriers to ...
Spoiler alert: Even after rallying +62.67% in November, Haemonetics stayed on the list of picks for December. But ProPicks AI doesn’t only pick US stocks. In fact, since the start of the year, our AI ...
Simultaneously, BGLC has obtained exclusive, perpetual rights to manufacture, market, and distribute VitaGuard™ across all ASEAN markets, solidifying the Company as the sole provider of this advanced ...
Why a 2026 Boardroom Risk Index Matters Now By the start of 2026, CEOs are no longer treating shocks as outliers; they see ...
Results from three studies together suggest progress in identifying diet, supplementation, and gut microbiome signatures ...
The South African on MSN
Falling forward: Rachel Kolisi announces new movement
A year after her split from Springboks captain Siya Kolisi, Rachel has launched a movement titled 'Falling Forward'. Take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback